 like first off-the-shelf t-cell
immunotherapi initi coverag neutral
messag atara develop novel t-cell immunotherapi cancer
autoimmun viral diseas valu proposit lead candid tab-
cel off-the-shelf therapi includ repeat dose limit side effect cost
effect also ebv-target candid ms emerg
view ms associ ebv though remain unclear associ
caus attribut lower probabl success program base
discuss kol given valuat recent stock move initi
initi neutral rate atara hebrew
diadem diadem crown royalti atara biotherapeut focus
develop allogen third-parti antigen-specif t-cell cellular therapi
platform develop atara design provid healthi immun system capabl
patient whose immun system compromis unabl identifi diseas target
product candid deriv cell donat healthi individu
expand bank inventori yet maintain abil recogn antigen
cell prepar day infus partial match hla human
leukocyt antigen patient recipi atara specif design patient treatment
algorithm base upon hla match found lead optim respons
infus patient cell grow destroy diseas ultim reced
atara platform quit versatil viral non-vir target condit relat
blood solid tumor well infecti autoimmun diseas compani t-
cell product candid licens memori sloan ketter cancer center msk
june technolog know-how acquir qimr berghof medic
research institut brisban australia octob septemb see
licens collabor agreement section page technolog know-how
enabl develop epstein-barr viru epv virally-associ cytotox
lymphocyt indic outsid cancer includ multipl sclerosi ms
invest thesi atara develop platform
immunotherapi collect healthi donor expos select viral cancer
antigen immunotherapi manufactur advanc store inventori
manufactur lot provid therapi numer potenti patient atara util
proprietari cell select algorithm select appropri set cell use base
patient uniqu immun profil unlik t-cell therapi minim prepar
time therapi may deliv recipi without need prior immun
suppress advanc program set follow stem cell solid organ
transplant atra immunotherapeut known tabelecleucel
develop treatment transplant patient develop epstein-barr viru
ebv cancer post-transpl lymphoprolif diseas ptld yet fail rituximab
antibodi deplet cell immunotherapi also use
treat ebv-associ hematolog solid tumor includ nasopharyng
carcinoma npc off-the-shelf autolog patient-deriv
respect atra immunotherapi potenti treatment multipl sclerosi
program cancer viral infect also develop
model assum tabelecleucel come market ptld npc
peak sale approxim billion billion respect year
percent probabl success indic base discuss kol
assumpt primari progress ms support market entri
peak sale excess billion current model percent probabl success
program combin assumpt gener dcf valuat
given share price current initi neutral rate
page analyst certif import disclosur
atara technolog platform deriv decad experi
memori sloan ketter msk qimr berghof australia compani
employ allogen off-the-shelf approach bioengin t-cell
healthi donor rapidli deliv cell inventori patient
requir pre-treat atara t-cell immunotherapi use common
technolog cell collect healthi donor expos
select viral cancer antigen activ viru case point
attract cytotox t-cell viral antigen activ t-cell
expand character store futur use provid ready-
to-us option patient
t-cell product candid design select recogn elimin
cancer diseas cell without effect healthi cell off-the-shelf
approach differ autolog treatment autolog therapi extract
modifi cell specifi patient follow redeliveri modifi
cell allogen immunotherapi provid read-to-us t-cell pre-built
inventori abil treat numer patient singl set cell
access allow rapid treatment atara technolog allow
deliveri engin t-cell patient inventori within day atara
observ safeti profil character treatment-rel seriou
advers event sae evid cytokin releas syndrom date
technolog first licens msk construct t-cell broadli target
recogn ebv cmv viral antigen tumor associ antigen
wilm tumor product candid develop util
technolog tabelecleucel formerli
second t-cell technolog licens qimr berghof employ select
antigen target develop t-cell target specif ebv cmv hpv bk
viral antigen atra product candid util technolog includ
engin t-cell product manufactur prior administ
patient store inventori cytotox t-cell librari creat
develop program initi healthi white blood cell peripher blood
mononuclear cell pbmc collect third-parti parti donor figur
b-cell donor separ expos specif
strain ebv viru order manufactur ebv transform lymphoblastoid
cell line ebv blcl irradi prevent growth co-
cultur t-cell deriv donor co-cultur process
blcl activ t-cell present ebv antigen t-cell figur
t-cell receptor identifi antigen interest becom
activ expand significantli upon activ t-cell unabl identifi
antigen remain inact eventu die figur result
line enrich cytotox t-cell specif identifi target antigen
line assess cytotox human leukocyt antigen hla
restrict alloreact microbi steril fulli character cell
line cryopreserv store
futur use ready-to-us
immunotherapi librari cryopreserv inventori figur librari
contain rel low amount ready-to-us line provid broad
coverag match patient individu immun profil
manufactur group cell provid abil treat variou patient figur
page analyst certif import disclosur
administr third-parti donor lymphocyt contain high
proport allospecif t-cell potenti result toxic graft
desir ebv-specif t-cell limit undesir off-target kill
cell result number potenti alloreact cell diminish may
limit risk toxic like gvhd
process util atara
tabelecleucel shown see figur similar process use
gener character cmv-specif t-cell atara
state plan employ manufactur process creat divers bank
target antigen interest
figur process gener tabelecleucel
engin
page analyst certif import disclosur
ctl mechan action
atara librari compris fulli human leukocyt antigen hla
character line cell select algorithm employ
compani select appropri line individu patient hla
genotyp atara use cell select algorithm develop msk identifi
appropri lot cell inventori use individu patient
select algorithm base patient uniqu immun profil match
key immun characterist patient uniqu profil patient-by-pati
basi figur follow select process administ
intraven either outpati inpati set figur
administ specif target diseas cell express target
antigen avoid healthi cell figur follow elimin target
cell expans figur longer encount target
antigen expans seiz number reced
figur mechan action
page analyst certif import disclosur
atara focus develop t-cell immunotherapi treatment
patient diagnos cancer autoimmun diseas viral diseas
compani advanc product candid develop tabelecleucel
evalu potenti treatment epstein-barr viru
ebv associ post-transpl lymphoprolif disord ebv-ptld
failur rituximab well ebv-associ hematolog solid tumor
nasopharyng carcinoma npc atara also develop t-cell
immunotherapi util antigen-target recognit technolog target
specif ebv antigen multipl sclerosi ms includ off-the-shelf
allogen autolog version addit product
candid develop includ wilm tumor
cytomegaloviru cmv
patient
atara advanc product candid tabelecleucel formerli known
cytotox lymphocyt target antigen express
epstein-barr viru ebv lead candid current develop
allogen off-the-shelf ebv-specif t-cell immunotherapi treatment
lymphoprolif disord ebv-ptld well ebv-posit
hematolog solid tumor includ nasopharyng carcinoma npc ebv
widespread human popul persist lifelong asymptomat
threaten condit estim median overal surviv ebv-ptld
follow hemapoiet stem cell transplant hct patient fail
rituximab-bas therapi day one- two-year surviv high-risk
ebv-ptld follow solid organ transplant sot patient
respect atara expect ebv-ptld market experi continu
page analyst certif import disclosur
observ higher
growth driven increas number transplant bone marrow peripher
blood umbil cord blood donat haploident transplant
well higher rate ptld due potent immune-suppress use
haploident transplant per compani world-wide transplant market
grow hct sot patient roughli
ebv-ptld follow hct sot patient address treatment
tabelecleucel expect hct/sot patient
 believ world-wide address patient popul
unit state compani expect
hct/sot patient eu address patient
popul eu
tab-cel ebv-ptld
sinc discoveri first human tumor viru epstein-barr viru ebv
implic develop wide rang b-cell lymphoprolif
transplant lymphoprolif disord hiv-associ lymphoprolif
healthi individu ebv quit widespread even ebv-driven diseas
absent individu t-cell devot keep ebv check
incid
lymphoprolif diseas transplant patient solid organ bone
marrow ebv driven viral infect post-transpl lymphoprolif
diseas ptld exploit sever strategi ensur persist infect name
prevent death infect cell increas prolifer cell
maintain infect reservoir evas immun system
multipl line evid suggest ebv infect major pathogen
role ptld includ ebv infect evid ptld patient
decreas cytotox lymphocyt increas ebv viral load
correl ptld develop treatment ptld autolog
ebv-specif result reduct viral load tumor size nearli
case ptld occur follow hematopoiet stem cell transplant hct
ebv posit approxim ptld case occur follow solid
organ transplant sot ebv posit ptld cay develop one year
follow stem cell transplant solid organ transplant may also peak
solid organ transplant year approxim ptld occur
given major ptld occur patient receiv transplant
appear result infect reactiv latent viru result
suppress immun system first line approach treat ptld
modul immunosuppress approach induc tumor regress
patient paya cv et al transplant patient high
ebv-dna viral load modul immunosuppress often practic
routin order prevent occurr ptld manag patient
ptld fail reduct immunosuppress often
rituximab case chemotherapi use rituximab appear
significantli chang therapeut approach ptld mani case patient
given rituximab without chemotherapi may respond percent patient
show drop ebv viremia howev percent patient
page analyst certif import disclosur
one two year surviv follow incomplet respons rituximab
patient high risk ebv-ptld solid organ transplant
earli trial ptld
doubrovina colleagu attempt understand adopt immunotherapi
unselect ebv-specif cell could induc remiss biopsy-proven
ebv lymphoma allogen cell transplant doubrovina et al blood
initi experi doubrovina young group
memori sloan ketter msk evalu patient ebv-lymphoma
achiev durabl complet remiss adopt transfer peripher blood
mononuclear cell pbmc contain unselect cell ebv-
seroposit transplant donor donor leukocyt white cell infus
dli review group perform similar therapi
howev report percent patient establish diseas
rooney colleagu introduc use ebv-specif cytotox
cell ebv-ctl creat laboratori vitro gener specif immun
collect administ ebv-ctl prophylaxi
patient risk none patient develop gvhd ebv-
lymphoprolif diseas ebv-lpd furthermor also success
treat patient ebv viremia clinic evid ebv-
lymphoprolif diseas eight patient biopsy-proven lpd
doubrovina publish detail studi allogen stem cell transplant
patient patholog confirm ebv-lymphoprolif diseas
patient treat either donor leukocyt infus ebv-ctl
patient group differ significantli group treat donor
leukocyt infus dli median age year wherea median age
ebv-ctl group year second differ dli group
consist predominantli recipi hla-match transplant
ebv-ctl group compris patient receiv hla-dispar
graft would high risk sever gvhd treat
unselect dli sustain respons seen percent patient
treat dli comparison percent patient treat ebv-
data dissimilar key discuss point
possibl treat patient ebv-ctl allogen donor provid
excel outcom monitor gvhd
phase ebv-ctl msk
prockop other treat solid organ transplant patient stem
cell transplant patient phase trial document ebv
lymphoma patient fail rituximab treatment rituximab
chemotherapi solid organ transplant patient patient receiv
cours t-cell infus separ week hct patient
complet durabl respons sustain partial respons
stabl diseas solid organ transplant patient durabl
complet respons durabl partial respons ebv-specif rose
blood respond patient ebv-ctl cours patient
progress diseas one cycl patient partial respons
receiv ebv-ctl second donor restrict differ hla allel
patient cr pr progress requir subsequ therapi
page analyst certif import disclosur
conclus suggest adopt transfer hla partial match ebv-ctl
cryopreserv bank msk restrict hla allel express
patient diseas induc durabl regress ebv-gener
lymphoma refractori rituximab without chemotherapi high
proport transplant patient prockop et al clin oncol suppl
phase clinic develop ebv-ptld
tabelecleucel tab-cel program advanc hematolog solid
tumor tab-cel current evalu two phase trial initi
januari separ indic hematolog malign ebv-ptld
transplant match follow solid organ transplant sot allel
three clinic site open enrol match
allel trial enrol expect later expand addit
site well eu canada australia current plan
launch eu tab-cel first off-the-shelf t-cell immunotherapi begin
phase develop unit state primari endpoint phase
trial object respons rate orr orr result phase trial
expect first half primari complet trial
expect novemb per clinicaltri gov addit atara plan
submit condit market author tab-cel rituximab-
refractori ebv-ptld post allohct eu first half compani
alreadi begun pre-commerci prepar plan submiss
basi data phase phase trial conduct
memori sloan ketter cancer center msk support data
on-going phase trial compani also plan phase trial
evalu tab-cel treatment ebv-ptld front-lin set
model market entri tabelecleucel treatment ebv-ptld follow hct
sot assign probabl success
commerci tab-cel indic see figur given
primari complet phase match allel trial expect
novemb accord clinicaltri gov expect market entri
approxim month later
figur risk-adjust tab-cel revenu estim ebv-ptld
page analyst certif import disclosur
tabelecleucel potenti first commerci avail allogen
immunotherapi well first fda- ema-approv therapi
treatment ebv-ptld tab-cel receiv orphan breakthrough
design fda februari ebv-ptld follow allogen
hematopoiet cell transplant hct orphan advanc therapi medicin
product atmp design ema well access prioriti medicin
regulatori support prime ebv-ptld follow allohct ema
octob addit drug candid receiv posit regulatori
feedback health canada support submiss tabelecleucel
posit data ebv-ptld
tab-cel also evalu patient ebv-associ tumor solid
tumor burkitt lymphoma hodgkin lymphoma dlbcl
on-going multicent expand access protocol eap trial complement
result on-going multicent eap studi tab-cel patient ebv
associ cancer american societi hematolog annual meet
abstract importantli result patient ebv ptld
consist tab-cel profil observ phase trial conduct
msk safeti efficaci result present patient phase
trial popul six patient ebv-ptld follow allohct six patient
ebv-ptld follow sot data demonstr orr
patient rituximab-refractori ebv-ptld follow sot
patient respond treatment orr observ
patient rituximab-refractori ebv-ptld follow allohct
patient respond treatment addit patient ebv-ptld follow
hct remain aliv unevalu due lack post-baselin assess
estim one-year overal surviv os patient ebv ptld
follow hct sot treat tab-cel tab-cel gener well-
toler patient popul
tab-cel ebv-npc
addit ebv-ptld atara plan util tab-cel potenti
treatment metastatic/recurr nasopharyng carcinoma npc
cours solid tumor npc type head neck cancer nearli case
common form npc non-keratin ebv posit standard
treatment npc typic includ radiat therapi without platinum-
base chemotherapi histor median surviv metastat diseas follow
fail chemotherapi approxim month current
approv medicin specif treatment diseas estim
approxim patient metastat recurr type npc
uk franc germani itali spain roughli asia primarili
april compani enter agreement merck buy
evalu tab-cel combin mrk
keytruda potenti treatment platinum-resist recurr ebv-
associ npc anticip initi phase trial tab-cel
combin merck checkpoint inhibitor keytruda treatment
npc second half model market entri tabelecleucel
treatment ebv-npc assign probabl success
commerci tab-cel indic see figur
page analyst certif import disclosur
figur risk-adjust tab-cel revenu estim ebv-npc
asco posit data ebv-npc
compani collabor investig msk present posit clinic
result phase studi evalu use tab-cel monotherapi
metastat npc patient fail line previou therapi data
present american societi clinic societi meet
abstract median follow month patient
receiv treatment remain aliv kaplan-mei surviv estim
two year orr object respons rate observ
complet respons cr partial respons pr evid t-cell
expans follow administr also observ histor median
surviv rate rang month metastatic/recurr follow standard
chemotherapi npc patient
multipl sclerosi
ebv role multipl sclerosi
multipl sclerosi common chronic inflammatori demyelin diseas
insul cover nerv cell brain spinal cord
damag caus sever progress disabl particularli young peopl
insul cover known myelin evid infect
epstein-barr viru ebv play major role develop ms pender
neuroscientist epstein-barr viru ubiquit double-
strand dna herp viru yet uniqu among human virus
capabl infect activ clonal expand persist latent
lymphocyt lifetim infect person ebv util
normal pathway b-cell differenti initi link ebv ms
support increas risk ms individu histori
mononucleosi elev serum titer antibodi ebv nuclear
antigen higher preval ebv infect ms case control
page analyst certif import disclosur
three categori multipl sclerosi relaps remit ms rrm
secondari progress ms spm primari progress ms ppm
progress ms includ ppm spm sever form ms limit
therapeut treatment option character continu progress
worsen symptom often result physic disabl time
approxim one million peopl world-wide affect pm sourc nation
multipl sclerosi societi spm patient initi diagnos rrm
howev time continu diseas progress result develop
spm ppm patient continu diseas progress begin
time initi diseas diagnosi although exist approv medicin pm
 mitoxantron spm ocrelizumab ppm simponimod
phase trial spm believ still remain substanti unmet
risk associ ebv ms
appear associ ebv ms higher ebna-
titer increas level mononucleosi almost associ
ebv infect ms one studi even indic seroconvers
prior diseas onset howev point evid ebv dna
alter ebv reactiv t-cell respons highli debat
scientif commun studi show differ oppos result
therefor question aris whether associ could confus
causat first simpl question ask peopl
suffer ms given high preval ebv human popul
may partial explain presenc absenc certain hla allel
ms patient ebv infect regardless genet predisposit
account ms case one possibl could potenti random
integr ebv genom human cell distinct diseas outcom
viral dna also exist linear circular form depend viral cycl
ebv shown randomli integr vitro b-cell line caus
methyl chang note ebv genom seem preval
episom integr dna believ may account
oppos find exist non-exist ebv sinc
dna detect reli certain viral sequenc may get disrupt
genom integr process still leav molecular mimicri plausibl
explan molecular mimicri theori describ viral
pathogen antigen structur similar host human protein
virus asid ebv strongli implic molecular mimicri
lymphocyt choriomeningit viru lcmv lcmv antigen
similar mbp ebv antigen vs lcmv antigen meet
import criteria mimicri includ surfac access antigen
flexibl hydrophob hydrophil epidemiolog factor favor
lcmv higher preval increas distanc equat increas
incid region peak ms incid lastli seem low
concord ident twin ms would share ident risk factor could
indic environment factor low infect lcmv ebv
anoth potenti explan molecular mimicri dual express two
tcr two differ chimer tcr express individu t-cell one
tcr recogn viral antigen tcr recogn mbp howev
note japan rate ms low ebv infect rate high
may explain homogen set hla allel japanes
popul higher propens maintain potenc ebv howev
would rule involv virus lastli ms rare
children would suggest ebv infect alon insuffici trigger
page analyst certif import disclosur
diseas cusik et al clin allergi immunol burnard et al ms
alter immun respons ebv ms b-cell
t-cell respons ebv ms patient decreas might predispos
patient develop ms allow accumul ebv infect
autoreact b-cell thu boost t-cell immun ebv
vaccin transfer ebv-specif cytotox t-cell may
benefici prevent treatment ms note viewpoint
contest anoth studi demonstr differ ms patient
healthi subject term t-cell respons hatfield
neuroimmunol strikingli b-cell activ ms patient show higher
immort rate vitro inact ms patient healthi subject
suggest integr ebv genom impair t-cell respons led
use singl patient promis durabl result
note patient number extrem limit make gener
conclus pender propos gener theori etiolog chronic
autoimmun diseas ebv infect autoreact b-cell migrat
certain tissu tissu produc pathogen autoantibodi
princip act antigen present cell guid molecular mimicri
t-cell persist due antigen present b-cell provid surviv signal
lead prolifer autoreact t-cell produc cytokin
recruit immun cell result tissu damag attack myelin
howev notion stand three main prerequisit ms patient fail
clear regul ebv manner healthi subject molecular
mimicri occur ebv b-cell infect ebv must resid brain
point controversi studi argument
howev note agent gener deplet b-cell antibodi
rituximab ocrelizumab ofatumumab shown efficaci ms patient
clearli underlin notion b-cell involv etiolog
diseas although role ebv remain unclear could altern
modifi hypothesi ebv episom integr viral genom dna
replic ineffici result loss ebv infect descend
b-cell round cell divis thu ebv-fre memori b-cell
may stem ebv memori b-cell lost viral episom
ebv-fre memori cell prolifer recogn antigen
caus inflamm ms origin antigen howev unclear
could either human pathogen ebv relat laurenc benito-
leon ms relat disord
view ms-treat physician
spoke two neurologist includ assist professor neurolog
harvard medic school clinic director partner multipl
sclerosi center well professor neurolog robert wood
johnson medic center collect treat see multipl
sclerosi patient per year cours major patient see
relaps remit ms percent /- small fraction approxim
percent patient primari progress tend differ
opposit treatment paradigm two paradigm escal versu
induct instanc one physician favor much aggress
induct treatment earli relaps remit ms treatment
moder rrm patient might includ gilenya tecfidera avers
prescrib ocrevu ocrelizumab fact patient insur
page analyst certif import disclosur
reimburs cost drug typic also use ocrevu spm
also ppm latter two gener substanti differ
pathophysiolog contrast physician tend treatment
approach follow escal milder drug given earlier stage
therapi follow aggress agent patient fail therapi
ask view ebv caus agent ms
adult ms ebv necessari cofactor case pediatr
patient suggest hypothesi ebv causat
proven exampl mononucleosi better
increas develop ms associ like
explan greater reactiv viru sit latent form
like cell also thought ebv infect cell present
antigen surfac may mean therapi direct ebv
express cell may fact total diminish ms genome-wid associ
studi seem correl chang mutat mhc suggest
autoimmun process support viral infect
etiolog agent rituximab moreov ocrelizumab
antibodi deplet bodi b-cell howev improv diseas
primari progress patient percent
improv howev despit deplet cell improv
diseas progress diseas continu progress ideal cell
harbor ebv elimin
conclus dilig suggest medic commun yet
prove pender hypothesi support ebv caus ms
degre hypothesi incred forward think claim one physician
still earli attempt explain ebv caus base limit
studi date
competit landscap ms
studi rituximab ms promis result drove interest b-cell deplet
strategi treat ms patient result off-label use rixtuximab
treat primari relaps ms rituximab bind express
b-cell fact rituximab shown specif reduc b-cell within
peripher blood cerebrospin fluid primari progress ms instead
develop rituximab mous antibodi roch rhhbi focus
develop human antibodi ocrelizumab receiv fda
approv treatment patient relaps primari
progress form ms primari progress ms account
overal popul ms cours diseas differ patient
relapsing/remit secondari progress form ms progress
consist mainli gradual worsen neurolog disabl symptom onset
although relaps may occur mitoxantron avail gener
medic approv patient secondari chronic progress
progress relaps worsen relapsing-remit ms unit state
sever treatment option exist relaps form ms includ interferon
glatrim acet nv teva teva tecfidera lemtrada sni
lemtrada also deplet b-cell deplet lymphocyt gener
b-cell nation ms societi access march
page analyst certif import disclosur
